



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/144,886	08/31/1998	JAMES D. MARKS	2307E-826US	5313

22798 7590 07/30/2002

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P O BOX 458
ALAMEDA, CA 94501

EXAMINER

MINNIFIELD, NITA M

ART UNIT PAPER NUMBER

1645

DATE MAILED: 07/30/2002

24

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---------------------------------------------------	---------------------

EXAMINER

ART UNIT	PAPER
----------	-------

24


DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The reply filed on May 13, 2002 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): the Response to Restriction Requirement did not elect a specific SEQ ID NO as requested. It is noted that a functional antibody requires the appropriate CDRs and framework regions. Applicant is required to elect a single species as it reads on a clone (e.g. C25, S25, C39, 1C6, 1F3 or any of the clones set forth in Table 4) or a particular combination of CDR and framework (e.g. VH, VL, and framework region 3). With regard to a particular combination, Applicant should specify them by nucleotides of SEQ ID NO. Applicants should elect a specific SEQ ID NO, not the countless variations set forth in the claims and Table 4. In the interest of compact prosecution, Applicant is invited to provide claims as they read on functional antibodies by setting forth particular CDRs and framework regions.

See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).


M. M. Winnifield
Primary Examiner
Art Unit: 1645
9/22/02